C83.20 Mixed small and large cell (diffuse) non-Hodgkin's lymphoma, unspecified site

Name of the Condition

• Mixed small and large cell (diffuse) non-Hodgkin's lymphoma, unspecified site
• Also known as ICD-10 code C83.20

Summary

Mixed small and large cell (diffuse) non-Hodgkin's lymphoma is a subtype of non-Hodgkin lymphoma characterized by the malignant proliferation of both small and large lymphoid cells in a diffuse pattern. It typically involves abnormal growth of B-cells or T-cells in lymph nodes or other lymphoid tissues, without forming follicular structures. This condition is part of the broader category of non-follicular lymphomas and may present with variable clinical behavior depending on the specific cell composition and distribution.

Causes

The exact cause of mixed small and large cell (diffuse) non-Hodgkin's lymphoma remains unknown. It is thought to involve genetic mutations or abnormalities in lymphoid cell development, though specific triggers are not well-defined. Research suggests potential links to immune system dysregulation or prior infections, but no definitive etiology has been established.

Risk Factors

• Age: More common in older adults.
• Family history of lymphoma.
• Prior exposure to radiation or certain chemicals.
• Chronic infections, such as hepatitis C or HIV.
• Immunosuppressive conditions or treatments.

Symptoms

• Swollen, painless lymph nodes.
• Unexplained weight loss.
• Fever.
• Night sweats.
• Fatigue.
• Loss of appetite.

Diagnosis

Diagnosis involves a combination of physical examination, imaging tests (e.g., CT or PET scans) to identify affected areas, biopsy of lymph nodes or tissues for laboratory analysis, and blood tests to assess overall health and detect abnormal cell markers. Histopathological examination is critical to confirm the mixed small and large cell composition and diffuse pattern.

Treatment Options

• Chemotherapy: Systemic drugs to target and kill cancer cells.
• Immunotherapy: Uses the body's immune system to fight cancer cells.
• Radiation Therapy: High-energy radiation to target localized disease.
• Stem Cell Transplant: For eligible patients, to replace damaged bone marrow.
• Targeted Therapy: Drugs that target specific molecular abnormalities in cancer cells.

Prognosis and Follow-Up

Prognosis varies based on factors such as age, overall health, and response to treatment. Regular follow-up is essential to monitor for recurrence or progression. Long-term surveillance may include periodic imaging and blood tests.

Complications

• Infection due to weakened immune system.
• Anemia or thrombocytopenia from bone marrow involvement.
• Organ dysfunction if lymphoma spreads to vital organs.
• Treatment-related side effects (e.g., nausea, fatigue).

Lifestyle & Prevention

• Maintain a balanced diet to support overall health.
• Avoid known carcinogens, such as tobacco or excessive alcohol.
• Practice good hygiene to reduce infection risk.
• Stay up-to-date with vaccinations, as recommended by a healthcare provider.

When to Seek Professional Help

Seek medical attention if you experience persistent swollen lymph nodes, unexplained weight loss, fever, or night sweats. Early evaluation is important for timely diagnosis and treatment.

Tips for Medical Coders

When coding for C83.20, ensure the documentation specifies "mixed small and large cell (diffuse)" and "non-Hodgkin's lymphoma" with an unspecified site. Verify that the diagnosis aligns with the histopathological findings and clinical presentation. Document any relevant details about the lymphoma's behavior or treatment to support accurate coding.